Streetbeat News

FWBI

First Wave BioPharma Inc

https://www.azurrx.com/

CEO

James Sapirstein

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.

Open

2.93

Mkt cap

Volume

56K

High

3.04

P/E Ratio

-0.06

52-wk high

60.00

Low

2.84

Div yield

N/A

52-wk low

2.33

Nauticus Robotics has announced an offshore service agreement with Shell, causing KITT's stock to rise by 34%. First Wave BioPharma has announced an exclusive global license agreement for Capeserod from Sanofi, leading to a 100% increase in FWBI's stock. OKYO Pharma has announced a public offering of ordinary shares, resulting in a 34% decrease in OKYO's stock.

Portfolio Pulse from ryanfaloona@benzinga.com

September 14, 2023 | 12:35 pm

First Wave BioPharma has entered into a license agreement for capeserod with Sanofi, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:50 am

First Wave Biopharma has entered into a license agreement with Sanofi. Sanofi could potentially receive up to $46M in development and regulatory milestone payments, and up to $235M in potential commercial milestone payments.

Portfolio Pulse from Charles Gross

September 14, 2023 | 10:24 am

First Wave BioPharma Inc (FWBI) has entered into a licensing agreement with Sanofi SA (SNY) for Capeserod, a drug that First Wave plans to repurpose for gastrointestinal indications. This follows disappointing results from First Wave's Phase 2 SPAN trial. The agreement includes a modest upfront payment, backend milestone payments, and single-digit royalties on net sales. First Wave will request a meeting with the FDA to establish a development and regulatory pathway for Capeserod.

Portfolio Pulse from Vandana Singh

September 14, 2023 | 10:00 am

First Wave BioPharma has entered into an exclusive global license agreement with Sanofi for Capeserod, a drug for gastrointestinal indications. The terms of the deal have not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 14, 2023 | 10:00 am

Shares of Tenon Medical, Inc. (TNON), Axcella Health Inc. (AXLA), Courtside Group, Inc. (PODC), Impel Pharmaceuticals Inc. (IMPL), MIRA Pharmaceuticals, Inc. (MIRA), Nuwellis, Inc. (NUWE), Hitek Global Inc. (HKIT), WANG & LEE GROUP, Inc. (WLGS), AEye, Inc. (LIDR), and Magenta Therapeutics, Inc. (MGTA) are trading lower in pre-market. The drop in TNON's shares is due to a proposed public offering of common stock.

Portfolio Pulse from Lisa Levin

September 11, 2023 | 12:10 pm

The article lists the stocks that gained and lost the most during Wednesday's mid-day trading session. Among the gainers were Palisade Bio, FOXO Technologies, iCoreConnect, Marin Software, and AeroVironment, which all saw significant increases in their share prices due to various positive developments. On the other hand, EZGO Technologies, Verb Technology Company, The Alkaline Water Company, Lion Group Holding, and Akoustis Technologies were among the biggest losers, with their share prices falling due to various negative developments.

Portfolio Pulse from Lisa Levin

September 06, 2023 | 5:16 pm

On Monday, 102 stocks hit new 52-week lows. The largest company by market cap to set a new 52-week low was AMC Enter Hldgs (NYSE:AMC), while the smallest was Aditxt (NASDAQ:ADTX). NovoCure (NASDAQ:NVCR)'s stock traded down the lowest, falling 32.92% to reach a new 52-week low. Allot (NASDAQ:ALLT) saw the sharpest rebound, as shares ascended 0.0%, reversing after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

August 28, 2023 | 5:54 pm

On Tuesday, 46 stocks hit new 52-week lows. The largest company by market cap to hit a new 52-week low was Moderna (NASDAQ:MRNA). The smallest firm by market cap to set a new 52-week low was American Rebel Holdings (NASDAQ:AREB). Polished.com (AMEX:POL) made the largest move down on the session, with shares plummeting 66.66% to reach its 52-week low. Brera Holdings (NASDAQ:BREA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low.

Portfolio Pulse from Benzinga Insights

August 04, 2023 | 10:08 am

On Wednesday, 59 companies hit new 52-week lows. The largest company by market cap to hit a new low was TC Energy (NYSE:TRP), while the smallest was China SXT Pharmaceuticals (NASDAQ:SXTC). AppHarvest (NASDAQ:APPH)'s stock fell the most, down 19.83%, while XOMA (NASDAQ:XOMA)'s stock bounced back, moving up 0.0% after hitting a new low.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 4:18 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.